Anticancer

Escin IA
Catalog No: CFN93368

Escin IA is a prodrug and its structure can be converted to desacylescin I by human intestinal bacteria and Lactobacillus brevis., desacylescin I as a biotransformation product shows potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression.

Desoxyrhaponticin
Catalog No: CFN90911

Desoxyrhaponticin is an agent that is potentially effective in controlling postprandial hyperglycemia in diabetes. Desoxyrhaponticin could be considered as a promising fatty acid synthase(FAS) inhibitor, it could inhibit intracellular FAS activity and downregulate FAS expression in human breast cancer MCF-7 cells.

Tubeimoside III
Catalog No: CFN90916

Tubeimoside III has anti-inflammatory, anti-tumor, and anti-tumorigenic activities, stronger than those of tubeimoside II. It has acute toxicity, stronger than that of tubeimoside II.

Tubeimoside II
Catalog No: CFN90915

Tubeimoside I, tubeimoside II, and tubeimoside III show anti-inflammatory, antitumor, and antitumor-promo ting effects.

Irinotecan hydrochloride
Catalog No: CFN90886

Irinotecan hydrochloride is a water soluble topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer.